Swiss pharma firm Roche Holding AG has reported that its third-quarter sales rose, due to a boost from its newer cancer medicines.
The world’s biggest producer of cancer-fighting drugs saw its third-quarter sales rise 1.8%, following flat sales for the first nine months of 2014. The latest results demonstrate the strong demand for its cancer drugs and emerging new products.
Group sales were reported at 34.8bn Swiss francs, almost identical to the 34.9bn francs taken in the same period last year. When measured in constant exchange rates however, sales actually rose 5% over the first three quarters of 2014.
Sales of Roche’s cancer medicines Herceptin, Perjeta and Kadcyla together increased 21%, while its sales of rheumatoid arthritis treatment Actemra/RoActemra rose 24%.
The company posted sales of 11.78bn francs for July to September, up from 11.57bn francs in the same period in 2013.
Severin Schwan, CEO, said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets.”